Krishna Bajjuri
Senior Director, Chemistry Sutro Biopharma
Seminars
- Leveraging a cutting-edge cell free platform and novel payload classes to discover high-DAR dual payload ADCs aimed at overcoming resistance to single payload ADCs
- Demonstrating synergistic efficacy of Topo1-based combinations with diverse mechanisms, including DDR inhibitors, to enhance anti-tumor activity
- Validating improved preclinical efficacy of dual payload ADCs across in vitro and in vivo/PDX models to support their potential in resistant tumor settings
Rejoin the Discovery Chemistry speakers for a closing panel discussion to break down the key learnings and future directions in ADC chemistry and MoA innovation. Listen and engage with your fellow attendees as they discuss showing promise within novel cytotoxic, non-cytotoxic and dual payload ADCs, and what still needs to be proven to unlock differentiation to combat patient resistance.
At the end of the main conference days, rejoin the discovery chemistry speakers for a closing panel discussion to break down the presentations and future directions in ADC chemistry innovation. Listen and engage with your attendees as they discuss what’s up-and-coming across cytotoxic and non-cytotoxic ADC payloads, dual payload combinations, and innovation in ADC linker and conjugation chemistry.
